Ethos
Access for All
BioViva believes that everyone should have access to the latest advances in medicine. Across modern life, technologies that were once expensive, rare, or available only to a small number of people have become increasingly affordable and commonplace. Cell phones, personal computers, automobiles, large-screen televisions, solar panels, and household appliances are familiar examples of this broader pattern. As technology advances and manufacturing becomes more efficient, the cost of producing new technologies can fall dramatically, making them accessible to an ever-growing number of people.
The same principle can apply to biotechnology. As demand increases and scientific and manufacturing capabilities improve, the production of novel therapeutics can become more efficient. Greater scale can encourage investment in better manufacturing processes, automation, improved delivery systems, and technologies that reduce production costs. BioViva intends to pursue this goal by investing in manufacturing capabilities designed to increase production capacity and reduce the cost of gene therapies. This includes technologies such as bioreactors that can support the production of larger quantities of viral vectors and other biological materials. Increasing manufacturing efficiency is an essential part of making advanced therapies more practical and, ultimately, more accessible.
Our goal is to continue pursuing better, and more efficient ways to manufacture these therapies while maintaining appropriate standards for quality and safety. We believe that innovation should not stop at the laboratory door. The ability to manufacture advanced therapies efficiently and at scale is just as important as discovering them. By investing in the technologies and infrastructure required for scale, BioViva intends to help move regenerative medicine from a highly specialized field toward broader access.
2. Ethical and Religious Concerns
We readily accept procedures designed to improve quality of life, restore vision, preserve mobility, repair damaged organs, or relieve chronic pain. A significant portion of society also accepts elective procedures performed primarily for cosmetic reasons. If we are willing to alter the human body to restore a function lost to disease—or simply to change an aspect of our appearance—why should the ethical boundary suddenly appear when the goal is to preserve function and health as we age?
Human life expectancy has increased dramatically with advances in medicine and public health. Clean water, sanitation, antibiotics, vaccines, improved nutrition, surgery, and countless other interventions have transformed diseases and conditions that were once accepted as unavoidable parts of life. Each generation has expanded the boundaries of what medicine can prevent, repair, or treat. There is no obvious reason that this progression must stop when we reach the biology of aging. If we accept medical intervention to prevent one cause of death, it is difficult to explain why intervening in another should automatically be considered unnatural or unethical.
Human progress has always involved challenging the limits imposed by nature. We learned to build tools, construct extraordinary cities, travel across oceans and into space, care for the sick, and reshape our environments to improve human life. Many ideas that now seem ordinary were once radical. The spherical Earth, powered flight, organ transplantation, and modern anesthesia each challenged prevailing assumptions in their time. Their acceptance did not diminish their revolutionary nature; it simply meant that society had incorporated them into everyday life.
None of this means that gene therapy should be exempt from ethical scrutiny. Powerful technologies demand careful research, appropriate oversight, informed consent, rigorous safety standards, and honest communication about risks and benefits. The ethical question should not be whether humans are allowed to intervene in biology—we already do so constantly. The more important question is whether we can develop these interventions responsibly and use them to reduce suffering, preserve health, and expand human freedom.
3. The Safety Of The Technology
Pharmaceuticals remain powerful medical tools, but approval does not mean that a therapy is free of risk. Even medicines that have undergone extensive regulatory review can produce serious adverse effects, and in some cases those effects can be fatal. This is not an argument against pharmaceuticals; it is a reminder that every medical intervention involves a balance between potential benefit and potential risk. Medicine has always advanced by developing new options when existing approaches leave patients with limited choices.
The United States provides an important example of why innovation must continue. Americans consume an enormous amount of medical care and prescription medication, yet the country continues to lag many other high-income nations in life expectancy. The OECD reports that U.S. life expectancy was 78.4 years in 2023, compared with an OECD average of 81.1 years. These numbers do not mean that conventional medicine has failed; they demonstrate that medical progress still has substantial room to improve.
Gene therapy offers one of those new avenues. The field is no longer theoretical or confined to basic laboratory research. Gene therapies have entered clinical development for a growing range of diseases, and human clinical trials are evaluating different approaches to delivering or modifying genetic material. After decades of research, scientists now have substantially more knowledge about vectors, dosing, manufacturing, immune responses, and the biological effects of genetic interventions than they did when the field first emerged.
As the technology has matured, researchers have developed increasingly sophisticated approaches to gene delivery and genetic modification. Viral vectors, nonviral delivery systems, mRNA, gene editing, and other platforms provide researchers with different ways to influence cellular function. At the same time, advances in manufacturing and quality control are making it possible to approach these therapies with greater precision and consistency. Gene therapy should therefore not be viewed as a finished technology, but as an evolving field in which each generation of research builds on what came before.
BioViva believes that responsible innovation requires both ambition and caution. Our objective is to explore new therapeutic possibilities while taking safety, manufacturing quality, regulatory requirements, and clinical evidence seriously. The promise of gene therapy is not that it eliminates risk, but that it may provide therapeutic options where existing approaches are insufficient. The opportunity before us is to continue pioneering those options responsibly, because improving the ways we prevent, treat, and ultimately overcome disease remains one of medicine’s most important goals.
4. Economy
The world is facing a profound demographic shift. Populations are aging, birth rates are declining in many countries, and the proportion of older adults is increasing relative to the working-age population. This trend is already reshaping economies, labor markets, pension systems, and healthcare. As more people live longer while fewer working-age people are available to support them, societies will face increasing pressure to maintain productivity and provide adequate care.
The consequences extend beyond retirement systems. A growing older population means greater demand for healthcare, long-term care, and assistance with age-associated conditions. At the same time, healthcare systems themselves depend on a workforce that is also aging. If large numbers of experienced workers leave the workforce because of age-related illness or disability, the resulting loss of knowledge and productivity can compound the demographic challenge.
BioViva believes that one part of the solution is to focus not simply on extending lifespan, but on extending healthspan—the years of life people can remain healthy, functional, and independent. Aging is accompanied by changes in cellular and molecular function, including alterations in telomere maintenance, mitochondrial function, genomic stability, cellular signaling, and tissue regeneration. By investigating these mechanisms through gene and cell therapies, BioViva seeks to explore whether maintaining healthier cellular function could help preserve physical and cognitive independence for longer.
The goal is not to force older people to remain in the workforce. It is to give people more healthy choices. A person who remains healthy and independent later in life may choose to continue working, mentor younger generations, start a new business, care for family, volunteer, create, or simply enjoy more years of active life.
5. Population Matters
A common objection to longevity research is that substantially longer lifespans would inevitably lead to overpopulation. Similar concerns have accompanied many major advances in medicine. When antibiotics, vaccines, and other life-saving technologies emerged, some feared that preventing premature deaths would create unsustainable population growth. Yet the demographic consequences of medical progress proved far more complicated. As societies became healthier and more prosperous, fertility rates generally declined, and population growth eventually slowed in many countries.
Demographic evidence today provides an important counterpoint to the assumption that longer lives automatically produce population explosions. Across much of the developed world, fertility rates have fallen substantially, and several countries are already experiencing population decline. Japan is one prominent example, but it is far from alone. Many nations are confronting aging populations, shrinking workforces, and fewer births rather than uncontrolled population growth. Longevity and fertility are not independent variables: as mortality falls and people gain greater confidence that their children will survive, families historically tend to have fewer children.
This does not mean that population pressures are irrelevant. A larger and healthier population would require food, energy, housing, transportation, and other resources. But human history demonstrates an extraordinary capacity to respond to those challenges through technological innovation. Agricultural productivity, refrigeration, sanitation, modern transportation, vertical construction, renewable energy, and increasingly efficient manufacturing have repeatedly expanded what societies can support. The question is therefore not simply how many people the planet can accommodate today, but how much human capability can expand alongside population.
We should therefore be cautious about treating longer human lives as a demographic catastrophe before the evidence supports that conclusion. Humanity has repeatedly responded to challenges created by its own progress with further innovation. A future in which people live longer and remain healthier would undoubtedly require adaptation, but adaptation is one of our species’ defining strengths.
6. Future of Employment
As new discoveries are made and new fields emerge, new industries and new kinds of work will follow. Throughout history, technological change has displaced some forms of labor while creating entirely new opportunities that were previously unimaginable. During the Industrial Revolution, cottage industries and agricultural work gave way to factories, manufacturing, and entirely new professions. The same pattern continued through the electrical age, the information revolution, and the rise of the internet. The jobs of tomorrow will not necessarily resemble the jobs of today.
The emergence of artificial intelligence may represent another profound transformation. AI is already changing how people work with information, analyze complex problems, create software and content, conduct research, and automate routine tasks. Rather than viewing AI solely as a replacement for human labor, we should also consider its potential to amplify human capability. As machines take on increasingly complex tasks, new roles will emerge around developing, directing, evaluating, and applying these systems. AI may also accelerate scientific discovery itself, allowing researchers to explore problems that would otherwise take decades to investigate.
The same dynamic is likely to occur across biotechnology and other emerging fields. Advances in nanotechnology, renewable energy, regenerative medicine, synthetic biology, advanced manufacturing, high-tech agriculture, robotics, space exploration, quantum computing, and artificial intelligence could create industries that are difficult to fully imagine today. Many of the occupations that will exist several decades from now have not yet been named, just as software engineers, social media managers, and many other modern professions would have been difficult to predict a century ago.
We believe humanity is entering an extraordinary period of technological convergence, in which advances in AI, biotechnology, computing, energy, engineering, and space exploration increasingly reinforce one another. There will undoubtedly be challenges and disruptions along the way, but history gives us strong reason to believe that human creativity responds to change by creating new possibilities. Rather than fearing a future in which technology leaves humanity behind, we should consider the possibility of a future in which technology gives more people the opportunity to remain healthy, productive, curious, and engaged for far longer than ever before. The next golden age may not be something we inherit, it may be something we build.
